tiprankstipranks
Advertisement
Advertisement
Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating
PremiumRatingsAnnovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating
2M ago
Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod
Premium
Company Announcements
Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod
2M ago
Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap
Premium
The Fly
Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap
2M ago
Annovis announces FDA meeting to discuss PDD program
PremiumThe FlyAnnovis announces FDA meeting to discuss PDD program
5M ago
Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s
Premium
The Fly
Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s
5M ago
Annovis Bio’s Strategic Advances and Insider Confidence Drive Buy Rating Amid Promising Alzheimer’s Treatment Progress
Premium
Ratings
Annovis Bio’s Strategic Advances and Insider Confidence Drive Buy Rating Amid Promising Alzheimer’s Treatment Progress
5M ago
Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD
PremiumThe FlyAnnovis Bio says all 84 sites fully activated for Phase 3 study in early AD
5M ago
Annovis Bio Announces Securities Purchase Agreement
Premium
Company Announcements
Annovis Bio Announces Securities Purchase Agreement
6M ago
Annovis Bio prices 1.67M shares at $2.05 in registered direct offering
Premium
The Fly
Annovis Bio prices 1.67M shares at $2.05 in registered direct offering
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100